Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034)

According to DelveInsight's analysis, the Lewy body dementia market is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as Neflamapimod (CervoMed), Zervimesine (Cognition Therapeutics), Nilotinib (KeifeRx), and others, and healthcare spending in the 7MM.

LAS VEGAS, July 10, 2025 /PRNewswire/ -- Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain. This buildup leads to cognitive impairments, visual hallucinations, Parkinson-like motor symptoms, and fluctuating attention levels.

LBD encompasses two main subtypes: Dementia with Lewy bodies (DLB), where cognitive issues arise before or at the same time as motor symptoms, and Parkinson's Disease Dementia (PDD), in which dementia appears more than a year after the onset of motor symptoms. While both share the same underlying pathology involving alpha-synuclein, they differ based on the sequence of symptom development.